Common features in published approaches to treatment of CVD in hemophilia
| Intervention/medication . | Factor replacement goal . |
|---|---|
| Percutaneous coronary intervention with therapeutic antithrombotic (UFH, bivalirudin, glycoprotein IIb/IIIa inhibitors) | Peak level of 80-100%, continue as long as therapeutic doses of antithrombotic are used (usually at least 48 h) |
| Dual antiplatelet therapy (aspirin + P2Y12 inhibitors) | Trough level of ≥30% |
| Single-agent antiplatelet therapy | Trough level of ≥5% |
| Coronary bypass surgery | Peak level of 80-100% by continuous infusion before, during, and after until sufficient wound healing has taken place |
| Intervention/medication . | Factor replacement goal . |
|---|---|
| Percutaneous coronary intervention with therapeutic antithrombotic (UFH, bivalirudin, glycoprotein IIb/IIIa inhibitors) | Peak level of 80-100%, continue as long as therapeutic doses of antithrombotic are used (usually at least 48 h) |
| Dual antiplatelet therapy (aspirin + P2Y12 inhibitors) | Trough level of ≥30% |
| Single-agent antiplatelet therapy | Trough level of ≥5% |
| Coronary bypass surgery | Peak level of 80-100% by continuous infusion before, during, and after until sufficient wound healing has taken place |